Drugs / 68Ga-grazytracer
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05000372 | Sep 2021 → May 2024 | cancer | Peking University Cancer Hospital & Institute | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-grazytracer | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05000372 ↗ |
| Route | Intravenous | “after intravenous injection of 2.96-3.7 MBq/kg body weight of quality-controlled 68Ga-grazytracer” NCT05000372 ↗ |